Management of Multiple Skin Boils in Lupus Nephritis
In a patient with lupus nephritis presenting with multiple skin boils (furunculosis), immediately initiate appropriate antibiotic therapy targeting Staphylococcus aureus while simultaneously evaluating and potentially reducing immunosuppression intensity, as serious infections are common in this population and associated with significant mortality.
Immediate Clinical Approach
Infection Management Priority
The presence of multiple skin boils in an immunosuppressed lupus nephritis patient represents a serious bacterial infection requiring urgent attention. Furunculosis is typically caused by Staphylococcus aureus 1, and in immunocompromised patients, these infections can progress rapidly.
Key actions:
- Culture the lesions before initiating antibiotics to identify the causative organism and guide targeted therapy
- Start empiric antibiotic coverage for MRSA if prevalent in your region, or anti-staphylococcal therapy if MRSA rates are low
- Incision and drainage for individual large furuncles as indicated 1
- Assess for systemic signs of infection (fever, bacteremia) - bacteremia occurs in approximately 14% of hospitalized lupus nephritis patients with infections 2
Critical Immunosuppression Assessment
You must immediately evaluate the patient's current immunosuppressive regimen and disease activity status. This is a critical decision point that directly impacts both infection control and lupus nephritis management.
According to the 2024 KDIGO guidelines, patients with lupus nephritis are typically on combination therapy including 3:
- Glucocorticoids (often moderate to high doses during active disease)
- Mycophenolic acid analogs (MPAA) OR
- Cyclophosphamide OR
- Calcineurin inhibitors (CNIs) OR
- Belimumab with MPAA or cyclophosphamide
Serious infections are strongly associated with lupus nephritis relapses (OR 2.33 for hospitalization, OR 3.47 for bacteremia) 2, and infection-related mortality occurs in approximately 5% of lupus nephritis patients 2.
Immunosuppression Modification Strategy
If Lupus Nephritis is Currently in Remission:
Reduce immunosuppression temporarily:
- Decrease glucocorticoid dose to the minimum necessary (ideally ≤5 mg/day prednisone equivalent per KDIGO guidelines) 3
- Consider temporarily holding or reducing MPAA/other agents until infection is controlled
- Do NOT discontinue hydroxychloroquine - this should be continued as it does not significantly increase infection risk and helps prevent flares 4
If Lupus Nephritis is Currently Active:
This represents a challenging clinical scenario requiring careful balance:
- Prioritize infection control - serious infections carry immediate mortality risk
- Reduce glucocorticoids to moderate-dose or reduced-dose regimens (see KDIGO dosing schemes: 0.5-0.6 mg/kg max 40 mg daily for reduced-dose) 3
- Continue maintenance immunosuppression at reduced intensity if possible
- Consider switching from cyclophosphamide to MPAA if patient is on cyclophosphamide, as MPAA may have a more favorable infection profile
Specific Infection Control Measures
For Recurrent Furunculosis Prevention:
Once the acute infection is controlled, implement strategies to prevent recurrence 1:
Decolonization protocols:
- Intranasal mupirocin ointment twice daily for 5-7 days
- Chlorhexidine body washes
- Consider treating household contacts if recurrent
Address predisposing factors:
- Optimize diabetes control if present
- Improve hygiene practices
- Identify and treat follicular abnormalities
Long-term suppressive antibiotics may be considered for truly recurrent cases after acute infection resolution
Monitoring and Follow-up
Close monitoring is essential:
- Daily assessment during acute infection phase
- Monitor for signs of systemic infection or sepsis
- Reassess lupus nephritis activity with urinalysis, proteinuria quantification, and serum creatinine
- Consider checking complement levels and anti-dsDNA if concerned about lupus flare
Common Pitfalls to Avoid
- Do not delay antibiotic therapy while waiting for culture results in an immunosuppressed patient
- Do not continue high-dose immunosuppression unchanged in the face of serious infection
- Do not assume all skin lesions are simple boils - consider other diagnoses including fungal infections (mucormycosis has been reported in lupus nephritis patients on immunosuppression) 5, calciphylaxis, pyoderma gangrenosum, or vasculitis
- Do not abruptly stop all immunosuppression as this may precipitate a lupus flare - taper strategically
- Do not forget prophylactic measures - ensure patient is on appropriate antimicrobial prophylaxis (PCP, fungal) per local protocols for their level of immunosuppression
Risk Stratification
High-risk features requiring hospitalization:
- Fever or systemic symptoms
- Multiple large lesions or rapidly spreading infection
- Facial involvement (risk of cavernous sinus thrombosis)
- Recent high-dose immunosuppression (especially cyclophosphamide or high-dose steroids)
- Chronic kidney disease stage IV-V
- History of previous serious infections